We are live on ! Find out more
O

OppenheimerFunds Portfolio holdings

AUM $80.4B
1-Year Est. Return 15.1%
This Fund
S&P 500
This Quarter Est. Return
+3.81%
1 Year Est. Return
+15.1%
3 Year Est. Return
+72.05%
5 Year Est. Return
+91.1%
10 Year Est. Return
AUM
$81B
AUM Growth
-$1.58B
Cap. Flow
-$3.65B
Cap. Flow %
-4.5%
Top 10 Hldgs %
16.13%
Holding
1,955
New
98
Increased
953
Reduced
772
Closed
100

Top Sells

Rank Stock Value
1
ETP
Energy Transfer Partners L.p.
ETP
+$786M
2
ABEV icon
Ambev
ABEV
+$368M
3
AAPL icon
Apple
AAPL
+$331M
4
BIDU icon
Baidu
BIDU
+$323M
5
JNJ icon
Johnson & Johnson
JNJ
+$285M

Sector Composition

Rank Sector Weight
1 Energy 15.38%
2 Financials 14.63%
3 Consumer Discretionary 13.36%
4 Healthcare 12.27%
5 Technology 10.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DATA
701
DELISTED
Tableau Software, Inc.
DATA
$12.3M 0.02%
200,000
AJG icon
702
Arthur J. Gallagher & Co
AJG
$63.7B
$12.2M 0.02%
213,584
-228,649
-52% -$12.9M
KEX icon
703
Kirby Corp
KEX
$7.95B
$12.2M 0.02%
182,104
+245
+0.1% +$16.7K
LEN icon
704
Lennar Class A
LEN
$20.4B
$12.2M 0.02%
239,672
+82,514
+53% +$4.06M
VRNT
705
DELISTED
Verint Systems
VRNT
$12M 0.01%
578,761
-1,792
-0.3% -$37K
WOW
706
DELISTED
WideOpenWest
WOW
$11.8M 0.01%
+680,667
New +$11.8M
MTW icon
707
Manitowoc
MTW
$516M
$11.7M 0.01%
486,802
+38,167
+9% +$893K
AVA icon
708
Avista
AVA
$3.47B
$11.6M 0.01%
274,244
+70,758
+35% +$2.95M
CLVS
709
DELISTED
Clovis Oncology, Inc.
CLVS
$11.5M 0.01%
123,264
-28,976
-19% -$1.77M
FMC icon
710
FMC
FMC
$1.42B
$11.5M 0.01%
182,094
+18,445
+11% +$1.19M
KYNB
711
Kyntra Bio
KYNB
$28.5M
$11.5M 0.01%
14,256
+7
+0% +$4.88K
MTDR icon
712
Matador Resources
MTDR
$6.31B
$11.5M 0.01%
537,885
+139,760
+35% +$3.17M
BLMN icon
713
Bloomin' Brands
BLMN
$680M
$11.5M 0.01%
+539,841
New +$11.1M
FRED
714
DELISTED
Fred's Inc
FRED
$11.4M 0.01%
1,233,036
+1,119,000
+981% +$14.9M
SAFE
715
Safehold
SAFE
$1.19B
$11.3M 0.01%
+192,972
New +$11.4M
RPM icon
716
RPM International
RPM
$13.7B
$11.3M 0.01%
207,277
+1,674
+0.8% +$89.5K
ASTE icon
717
Astec Industries
ASTE
$1.3B
$11.2M 0.01%
202,006
-239,381
-54% -$14.1M
SUPN icon
718
Supernus Pharmaceuticals
SUPN
$2.68B
$11.2M 0.01%
259,237
+252,683
+3,855% +$8.99M
NTES icon
719
NetEase
NTES
$76.5B
$11.1M 0.01%
+185,400
New +$10.6M
KITE
720
DELISTED
Kite Pharma, Inc.
KITE
$11M 0.01%
105,733
-15,277
-13% -$1.25M
LNT icon
721
Alliant Energy
LNT
$19.4B
$10.9M 0.01%
272,358
+27
+0% +$1.09K
SNV
722
DELISTED
Synovus
SNV
$10.8M 0.01%
244,674
+236,948
+3,067% +$9.96M
ARE icon
723
Alexandria Real Estate Equities
ARE
$8.88B
$10.8M 0.01%
89,800
+14,055
+19% +$1.64M
ALE
724
DELISTED
Allete
ALE
$10.8M 0.01%
150,268
+8,876
+6% +$630K
HIW icon
725
Highwoods Properties
HIW
$3.71B
$10.8M 0.01%
212,361
-287,161
-57% -$14.7M

Similar funds

OppenheimerFunds's Q2 2017 Portfolio in Review

As of Q2 2017, OppenheimerFunds held 1,955 positions worth $81B, down 1.9% from $82.6B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

OppenheimerFunds withdrew a net $3.65B in Q2 2017, closing 100 positions and reducing 772 holdings. Its most notable exit was Energy Transfer Partners L.p., an estimated $786M position sold in full.

By sector, the portfolio is most concentrated in Energy at 15% of assets, down from 17% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, OppenheimerFunds opened a new position in Antero Midstream worth $132M.

  • OppenheimerFunds's largest Q2 2017 buy was Antero Midstream: 5,990,120 shares worth $132M.
  • OppenheimerFunds added most to Energy Transfer Partners, L.P. in Q2 2017, an estimated $729M increase.
  • OppenheimerFunds's biggest Q2 2017 reduction was Apple, cutting an estimated $331M.
  • OppenheimerFunds fully exited Energy Transfer Partners L.p. in Q2 2017, selling an estimated $786M.
  • OppenheimerFunds's ten largest holdings make up 16% of its $81B portfolio in Q2 2017.
  • OppenheimerFunds opened 98 new positions and closed 100 in Q2 2017.
  • OppenheimerFunds's portfolio value fell 1.9% quarter-over-quarter to $81B.

Based on OppenheimerFunds's 13F filing for Q2 2017, filed 14 Aug 2017.